ASC
REGN icon

Atalanta Sosnoff Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Atalanta Sosnoff Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-85,728
Closed -$23.6M – 106
2013
Q4 		$23.6M Buy
+85,728
New +$24.7M 0.51% 52

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Atalanta Sosnoff Capital's REGN Position: Q1 2014 in Review

Atalanta Sosnoff Capital sold out of Regeneron Pharmaceuticals (REGN) in Q1 2014, closing a stake of 85,728 shares — an estimated $23.6M sold.

Atalanta Sosnoff Capital first reported a position in REGN in Q4 2013 and held it in 1 quarter. The position peaked at $23.6M in Q4 2013. 452 funds tracked by Wall St. Rank hold REGN as of Q1 2014.

  • Atalanta Sosnoff Capital reported no remaining Regeneron Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Atalanta Sosnoff Capital sold 85,728 Regeneron Pharmaceuticals shares in Q1 2014, an estimated $23.6M.
  • Atalanta Sosnoff Capital first reported a position in Regeneron Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Atalanta Sosnoff Capital's Regeneron Pharmaceuticals position peaked at $23.6M in Q4 2013.
  • 452 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2014.

Based on Atalanta Sosnoff Capital's 13F filing for Q1 2014, filed 9 Apr 2014.